ID3 and urinary bladder carcinoma: It has been reported that ID3 contributes to cancer progression by antagonizing the transcriptional activation of cyclin‐dependent kinase inhibitors (CDKIs), such as p15, p16, and p21.[35, 36] Hence, we explored whether ID3 regulates the expression of CDKIs in bladder cancer.